Sponsored by
GammaTile is a small implant placed in the brain at the time of resection surgery that delivers radiation right away instead of waiting weeks for standard post-surgery radiation. It was first cleared by the FDA in 2018 for both newly diagnosed and recurrent glioblastoma (GBM) and has been used in patients for several years. Now, GT Medical Technologies has started enrolling patients in the BRIDGES trial, a large randomized study to see whether GammaTile helps people with newly diagnosed GBM live longer compared with the current standard of care radiation.